<DOC>
	<DOCNO>NCT00929019</DOCNO>
	<brief_summary>1 . Rationale Immunotherapy apply ex vivo generate tumor antigen-loaded dendritic cell ( DC ) successfully introduce clinic . A limited , consistent , number objective immunological clinical response observe . Most successful result observe patient minimal residual disease , rather patient advance metastatic disease . Moreover , investigator ' preliminary result show presence tumor epitope specific T cell biopsies take delayed type hypersensitivity ( DTH ) reaction sit highly correlate prolong progression free survival ( PFS ) . Within uveal melanoma patient , group high risk metastatic disease identify basis tumor specific genetic change loss chromosome 3 . At present standard adjuvant systemic treatment available . Applying DC-based immunotherapy group high risk patient might reduce risk recurrence without interference current treatment guideline . 2 . Objectives In joint clinical study Radboud University Nijmegen Medical Centre ( RUNMC ) Rotterdam Eye Hospital , investigator aim determine vivo immunological response induce high risk uveal melanoma patient vaccinate mRNA-transfected DC . 3 . Study design This study open label non-randomized phase II intervention study . 4 . Study population The investigator ' study population consist HLA-A2 positive patient high risk uveal melanoma proven expression melanoma associate antigen tyrosinase and/or gp100 . 5 . Main study endpoint This exploratory study aim demonstrate proof principle . The first study endpoint vivo immunological response induce high risk uveal melanoma patient vaccinate mRNA-transfected DC , administer i.v./i.d . toxicity . Secondary study endpoint progression free survival , overall survival , toxicity .</brief_summary>
	<brief_title>Messenger Ribonucleic Acid ( mRNA ) Transfected Dendritic Cell Vaccination High Risk Uveal Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>histological document uveal melanoma HLAA2.1 phenotype ( intervention arm ) nonHLAA2.1 phenotype ( control arm ) melanoma express gp100 and/or tyrosinase high risk genetic profile ( loss chromosome 3 ) determine FISH interval since local treatment uveal melanoma &lt; 12 month sign liver metastasis determine diagnostic CTabdomen normal serum LDH sign cerebral metastasis bilirubin &lt; 25 micromol/l WHO performance scale 01 age 1875 year write informed consent expect adequacy followup pregnant lactating woman history second malignancy , except adequately treat basal cell carcinoma serious active infection autoimmune disease organ allograft concomitant use immunosuppressive drug know allergy shellfish</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>uveal melanoma</keyword>
	<keyword>chromosome 3</keyword>
	<keyword>high risk</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>adjuvant</keyword>
	<keyword>high risk genetic profile</keyword>
	<keyword>loss chromosome 3</keyword>
</DOC>